Partnership and licensing deals in radiopharmaceutical therapies surged to 3.5 times Q1 2025 levels in Q1 2026, with Bristol Myers Squibb, Eli Lilly and AstraZeneca backing high-potency alpha-emitting RLTs. Analysts warn on benefit-risk tradeoffs such as irreversible salivary gland damage and supply-chain hurdles compared to established beta emitters.
In Q1 2026, partnership and licensing deal values in the radiopharmaceutical sector rose to 3.5 times their Q1 2025 total, highlighting escalating interest from major pharma players including Bristol Myers Squibb, Eli Lilly and AstraZeneca in next-generation RLTs.
High-potency, short-range alpha emitters are generating excitement for potential efficacy gains, but experts emphasize the need to balance benefit-risk ratios and establish robust supply chains, unlike more established beta-emitting therapies such as lutetium Lu 177–based drugs.
Clinical data from early alpha-emitter trials revealed a high incidence of irreversible salivary gland damage, leading to persistent dry mouth and weight loss, prompting analysts to caution on long-term quality-of-life impacts when positioning these therapies earlier in treatment.
Wider adoption of RLTs requires a resilient isotope supply chain, clear reimbursement pathways and sufficient treatment sites with trained staff, as approval alone may not guarantee patient access or streamline development of next-generation radiopharmaceuticals.
